Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

1097603

USP

Cefazolin

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

Cephazolin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C14H14N8O4S3
Numéro CAS:
Poids moléculaire :
454.51
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

cefazolin

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

InChI

1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1

Clé InChI

MLYYVTUWGNIJIB-BXKDBHETSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cefazolin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Cefazolin for Injection
  • Cefazolin in Dextrose Injection
  • Cefazolin Sodium

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Resp. Sens. 1 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Nagaraju Konda et al.
Optometry and vision science : official publication of the American Academy of Optometry, 91(1), 47-53 (2013-11-12)
To investigate the utility of additional microbial analyses to detect the causative microorganism of microbial keratitis and to determine the strength of association between clinical variables. This retrospective study included 125 eyes of 123 people presenting with presumed infectious keratitis
T Osler et al.
Diseases of the colon and rectum, 29(2), 140-143 (1986-02-01)
The seventh case of probable cefazolin-induced pseudomembranous colitis is reported. Perforation of the colon necessitated sigmoid resection. The postoperative course was protracted, and illustrates the difficulty of managing advanced pseudomembranous colitis when the oral route of antibiotic administration is not
Cheng-Kun Wu et al.
PloS one, 8(4), e61666-e61666 (2013-05-01)
Antibiotic prophylaxis with norfloxacin, intravenous ciprofloxacin, or ceftriaxone has been recommended for cirrhotic patients with gastrointestinal hemorrhage but little is known about intravenous cefazolin. This study aimed to compare the outcome of intravenous cefazolin and ceftriaxone as prophylactic antibiotics among
Mack W Savage et al.
American journal of obstetrics and gynecology, 209(2), 108-108 (2013-05-29)
To identify risk factors for and outcomes of surgical site infections and cellulitis after abdominal hysterectomies. We used logistic regression analysis to analyze data from a case-control study of 1104 patients undergoing abdominal hysterectomies at a university hospital between Jan.
John D Turnidge
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 52(7), 917-924 (2011-03-24)
Clinical and Laboratory Standards Institute breakpoints for cefazolin against Enterobacteriaceae that were published in January 2010 have been revised by the Subcommittee on Antimicrobial Susceptibility Testing, based on the examination of recent data about in vitro activity, pharmacokinetic-pharmacodynamic characteristics and

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique